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ABSTRACT
Objectives: This study aimed to estimate the
prevalence of diabetes mellitus (DM) in hospitalized
patients with community-acquired pneumonia (CAP)
and its impact on hospital length of stay and in-
hospital mortality.
Research design and methods: We carried out a
retrospective, nationwide register analysis of CAP in
adult patients admitted to Portuguese hospitals
between 2009 and 2012. Anonymous data from
157 291 adult patients with CAP were extracted from
the National Hospital Discharge Database and we
performed a DM-conditioned analysis stratified by age,
sex and year of hospitalization.
Results: The 74 175 CAP episodes that matched the
inclusion criteria showed a high burden of DM that
tended to increase over time, from 23.7% in 2009 to
28.1% in 2012. Interestingly, patients with CAP had
high DM prevalence in the context of the national DM
prevalence. Episodes of CAP in patients with DM had
on average 0.8 days longer hospital stay as compared
to patients without DM (p<0.0001), totaling a surplus
of 15 370 days of stay attributable to DM in 19 212
admissions. In-hospital mortality was also significantly
higher in patients with CAP who have DM (15.2%)
versus those who have DM (13.5%) (p=0.002).
Conclusions: Our analysis revealed that DM
prevalence was significantly increased within CAP
hospital admissions, reinforcing other studies’ findings
that suggest that DM is a risk factor for CAP. Since
patients with CAP who have DM have longer
hospitalization time and higher mortality rates, these
results hold informative value for patient guidance and
healthcare strategies.
INTRODUCTION
Diabetes mellitus (DM) is a signiﬁcant public
health burden, representing one of the most
common chronic diseases worldwide and
being associated with high morbidity and
mortality.1 The increasing prevalence of DM
and other comorbidities has been suggested
as a driving factor for the rising burden of
infection-related hospitalizations.2–4 Respiratory
infections are among the major infections asso-
ciated with diabetes.5 Community-acquired
pneumonia (CAP) is one of the most fre-
quent infections requiring hospital admis-
sions in developed countries;6 it ranks
among the top causes of death and is a
major driver of healthcare utilization and
cost.7–9 In Portugal, a retrospective study with
data from 2000 to 2009 reported that admis-
sions for CAP represented 3.7% of total
admissions of adult patients.10 Association of
DM with CAP hospitalizations has been sug-
gested previously.8 9 11–14 However, informa-
tion regarding the burden and outcomes of
DM in patients with CAP, and particularly its
relationship with hospitalization and in-hospital
mortality, is still limited.
Recommendations of ﬂu and pneumococ-
cal vaccination of patients with DM by
medical societies and several health author-
ities reﬂect the notion that people with dia-
betes are at increased risk of respiratory
infections.1 Within the European context,
Portugal presents one of the highest rates of
DM. The PREVADIAB study estimated that
the nationwide prevalence of DM in 2009
was 11.7% within the adult population (20–
79 years).15 Since 2003, the annual rate of
new DM cases in Portugal increased by 3.8%
on average. 16 In 2012, people with diabetes
represented 14% of the patients admitted to
the Portuguese hospital public system, and
23.5% of in-hospital mortality involved patients
with DM.16
Robust information on the impact of DM
among the population hospitalized with CAP
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▪ Diabetes mellitus increases the risk for hospital-
isation of patients with community-acquired
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is critical to ascertain the differential risk of patients
with DM and to design effective preventive care strat-
egies. Hence, we have carried out a retrospective analysis
of the Portuguese hospital registers of adult patients hos-
pitalized with CAP between 2009 and 2012. We aimed to
estimate the prevalence of DM among this population
and the impact of DM on length of hospital stay and
in-hospital mortality.
METHODS
Data sources
Data were retrieved from the Central Administration of
the Health System of the Portuguese Ministry of Health
that contains administrative and clinical data on all
admissions to National Health System hospitals, covering
the vast majority of Portugal’s mainland population.
The clinical information, including case identiﬁcation
(namely the clinical diagnosis of CAP and DM) and
procedures, is encoded from the details of the hospital
discharge report by medical doctors who were specially
trained in hospital coding, using the International
Classiﬁcation of Diseases, 9th Revision Clinical
Modiﬁcation (ICD-9-CM).17 The coding is audited peri-
odically by the ACSS (Administração Central do Sistema
de Saúde; Central Administration of the Health System)
in Portugal. This type of methodology has been previ-
ously used and validated in other studies.10 Anonymized
data were extracted from the National Hospital
Discharge Database from 2009 to 2012. Research was
conducted according to the principles of the
Declaration of Helsinki. Anonymized data were retrieved
from an administrative database. Once it is not possible
to identify, by any means, an individual patient, ethical
approval was not required and informed consent not
sought.
Study population and eligibility
Subjects included in the study were patients aged 20–
79 years with CAP diagnosis as the main cause of admis-
sion (ICD-9-CM 480-486 and 487.0). Data for analysis
were clean from day cases and hospitalizations >90 days.
To avoid overestimation from repeated admissions, diag-
nostic codes recorded within 28 days of one another for
the same individual were attributed to a single infection
episode, with the index date deﬁned by the ﬁrst diagnos-
tic code. We excluded from the analysis individuals who
were immunocompromised by anticancer or immuno-
suppressive treatment (external cause of disease code
E933.1) and transplant recipients (V42) and patients
with HIV (ICD-9-CM 042-044). Within the selected sub-
jects, we looked for concomitant diagnosis of diabetes in
the discharge records (ICD-9-CM 250), to differentiate
two groups of individuals, CAP with or without DM.
Nationwide DM statistics from 2009 to 2012 were
retrieved from the national diabetes prevalence study
(PREVADIAB).15 For comparison purposes, age range
(20–79 years) and age stratiﬁcation (age groups: 20–39,
40–59 and 60–79 years) followed the PREVADIAB study.
Information on the population size of mainland
Portugal was provided by the Instituto Nacional de
Estatística (http://www.ine.pt) and corresponds to esti-
mates of the resident population at the end of each year,
according to age and sex.
Data analysis
CAP with DM (CAP-DM) was compared with CAP
without DM for age and gender biases, hospitalization
time and mortality rate, across age groups and over the
2009–2012 period. Categorical variables were described
using counts and percentages while continuous variables
were expressed as the mean and SD. The median and
IQRs are also shown to take into account the non-
normal distribution of continuous variables under ana-
lysis (Shapiro-Wilk test). Signiﬁcant differences between
groups were detected by χ2 test or Fisher exact test for
categorical variables, and by the Student’s t-test or
Mann-Whitney test for continuous variables, as appropri-
ate. Analysis of hospital length of stay and in-hospital
mortality used univariate analysis of variance (ANCOVA),
adjusted for age and gender. The Cochran-Armitage test
was performed for a trend analysis of diabetes prevalence
changes over time (from 2009 to 2012). All the calcula-
tions presented were obtained using the statistical soft-
ware package PASW Statistics 19.0 (SPSS Inc.) and the
Microsoft Excel 2007 spreadsheet (Microsoft Corp.,
Redmond, Washington, USA). A p value of <0.05 was con-
sidered statistically signiﬁcant. All reported p values are
two-tailed.
RESULTS
From the initial 157 291 registers of CAP admissions,
from 2009 to 2012 (37 989–40 200/year), after applying
the exclusion criteria and selecting the target age range
(20–79), we analyzed 74 175 episodes of CAP hospitaliza-
tions, of which 19 212 (25.9%) corresponded to people
with DM (table 1).
The median age of the cohort was 72 (IQR, 65–
76 years) for CAP-DM, and 67 (IQR, 53–75 years) for
CAP without DM, indicating that patients with DM were
signiﬁcantly older (p<0.0001). We performed an
age-stratiﬁed analysis of 2009–2012 data to ascertain
whether the observed effects are more prominent in
speciﬁc strata. In the three age groups (20–39; 40–59
and 60–79 years), patients with CAP-DM were always sig-
niﬁcantly older (p<0.0001) (table 2). Although the age
distribution was skewed to old ages both in patients with
CAP with or without DM, it is worth noting that the age
group 60–79 represented over 86% of the patients with
CAP-DM, while the age group 20–39 was under-
represented (1.2%) (table 2 and ﬁgure 1). The median
age showed a trend to increase from 2009 to 2012, most
prominently in patients with CAP without DM (from
66 years in 2009 to 69 years in 2012), but the patients
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with CAP-DM were always signiﬁcantly older (p<0.0001)
(table 3).
The prevalence of CAP, irrespective of DM
co-occurrence, was higher among men than women
(table 1). However, the male/female ratio was signiﬁ-
cantly different between the two groups (p<0.0001),
with patients with CAP-DM showing a lower proportion
of men (58.5%) when compared to patients with CAP
without DM (61.9%) (table 1). This gender difference
increased from the age group 20–39 years to 40–
59 years, then decreasing in the age group 60–79 years,
possibly reﬂecting the decreased male/female ratio in
the general elderly population (table 2). Nevertheless,
men were more likely to experience CAP infections than
women in all age groups. During the analysis period, the
percentage of males varied between 57.5% and 59.5% in
CAP-DM, and 60.6%–63.0% in CAP without DM (table 3).
Interestingly, the burden of DM in CAP was more pro-
nounced in women (25.1%) than in men (22.8%).
Analysis adjusted for sex and age revealed that the
average length of stay was signiﬁcantly longer in
CAP-DM cases (p<0.0001), with an average length of
stay of 12.0±10.5 vs 11.2±10.1 days. This difference was
observed for all age groups but was highest in the
younger age stratum (20–39 years; +2.5 days) in compari-
son with the older stratum (60–79 years; +0.2 days). In
the 2009–2012 period, the average length of stay was
consistently higher in CAP-DM cases when compared to
CAP without DM, with the difference in length of stay
varying from+0.8 to+1.0 days totalling an estimated
increase of 15 370 days of stay attributable to DM in over
19 000 episodes (table 3), which represent ∼0.93% of
total hospital admissions (according to Froes et al10).
Interestingly, in-hospital mortality (20–79 years),
adjusted for sex and age, was signiﬁcantly higher in
patients with CAP who have DM (15.2%) as compared
to patients with CAP without DM (13.5%) (p=0.002)
(table 1). From 2009 to 2012, in-hospital mortality was
always higher in patients with CAP who have DM (14.8–
16.0%) as compared to patients with CAP without DM
(12.7–14.3%) (table 3). However, when analyzing by age
group, increased mortality of patients with DM was only
observed in the youngest age group. Furthermore,
in-hospital mortality in older strata revealed that patients
with CAP without DM show a trend to higher mortality.
This apparent discrepancy is probably due to the under-
representation of the youngest age group (20–39 years)
in patients with CAP-DM (1.2%) as compared to patients
with CAP without DM (10.2%) (table 2).
We found that the DM burden in CAP episodes stead-
ily increased over time, from 23.7% in 2009 to 28.1% in
2012 (table 3), representing a trend of increasing DM
prevalence among patients with CAP (Cochran-Armitage
test; p value <2.2×10−16). This may result in part from
the impact of population ageing since, in our study,
there was an increase in the representation of indivi-
duals in the 60–79 years age group from 67.5% in 2009
to 75.4% in 2012 (data not shown).
DISCUSSION
Diabetes mellitus has been frequently associated with
respiratory infections. We performed a large cohort
retrospective study that allowed detailed nationwide esti-
mates of DM prevalence in CAP hospital admissions as
well as comparisons to national DM prevalence in
Portugal. We found a high burden of DM in patients
hospitalized with CAP (25.9%), in agreement with the
high rates obtained in previous studies of 21.4% and
16% performed elsewhere.12 18 The burden of DM
increased over the period under analysis (2009–2012),
similar to what was observed in a recent study estimating
the burden of CAP, between 1997 and 2011, in the
UK.19 In line with studies that suggest that patients with
DM are at higher risk for CAP (reviewed in8), we
observed that the DM prevalence in CAP admissions
between 2009 and 2012 was consistently higher, and
more than double, when compared to the estimations of
the DM prevalence in Portugal (ﬁgure 2).
Our study covered admissions from all Portuguese
public hospitals over a period of 4 years to analyze the
impact of DM in CAP hospitalizations. We corrected our
analyses for gender and age and excluded immunocom-
promised individuals. Nevertheless, these analyses have
Table 1 Patients with CAP with and without DM hospitalized in Portugal between 2009 and 2012 (age range 20–79 years)
CAP-DM CAP-without-DM p Value
n (%) 19 212 (25.9) 54 963 (74.1)
Mean±SD Age, years 69.4±9.2 62.7±14.9
Median (IQR) Age, years 72 (65–76) 67 (53–75) <0.0001
Male/female, n (%) 11 231/7981 (58.5/41.5) 34 027/20 936 (61.9/38.1) <0.0001
Mean±SD, hospitalization days 12.0±10.5 11.2±10.1
Median (IQR) hospitalization days 9 (6–14) 8 (5–13) <0.0001
In-hospital mortality, n (%) 2918 (15.2) 7427 (13.5) 0.002
Significant differences between groups were detected by means of χ2 test for categorical variables, and by the Student’s t-test or
Mann-Whitney test for continuous variables, as appropriate. Univariate analysis of variance (ANCOVA), adjusted for age and gender was
used to compare hospital length of stay and in-hospital mortality between the two groups.
Significant p values are highlighted in bold.
CAP, community-acquired pneumonia; CAP-DM, DM in CAP; DM, diabetes mellitus.
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several inherent limitations. The data are derived from a
database that did not contain direct clinical measures
and we did not have access to clinical records.
Therefore, we could not include in the analyses possible
confounding factors, namely related to diabetes and
CAP severity, therapies and vaccination, smoking history
or lifestyles. We have also to take into account that dia-
betes is a frequent cause for hospitalization, and that
this potential bias could overestimate the incidence of
diabetes in respiratory infections and lead one to
suspect that diabetes is a risk factor for susceptibility.20
In our study, case identiﬁcation was based in medical
record information following the international coding
system that was applied by speciﬁcally trained medical
staff in according a methodology that was previously vali-
dated.10 Thus, we reason that misclassiﬁcation in the
hospital discharge database is likely to be relatively
small, although underestimation of diabetes in hospital
settings has been reported elsewhere.21 Although we did
not follow a study design speciﬁc to compare the target
population with the general population,22 we consider
that contrasting our results with the general population
in Portugal will help to contextualize the burden of DM
in hospitalized patients with CAP.
In agreement with two prospective studies in
Spain12 18 we found that age distribution in CAP-DM
patients was skewed to older ages as compared to CAP
patients without DM, which reﬂects the age of DM
onset. The median age of CAP admissions showed a
trend to increase from 2009 to 2012, in accordance with
Froes et al,10 which also reported a 5% increase in the
average age of patients admitted with CAP between 2000
and 2009 in Portugal. As reported in other studies, CAP
infections affected more men than women.10 12 18
Interestingly, the prevalence of diabetes among CAP
admissions was higher in women than in men (25.1% vs
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Figure 1 Age distribution of CAP with diabetes and CAP
without diabetes (2009 to 2012) shows a stronger
skewedness to old ages in patients with CAP-DM. CAP,
community-acquired pneumonia; CAP-DM, DM in CAP; DM,
diabetes mellitus.
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22.8%), as opposed to what is observed in the general
population (10.2% vs 14.6%) (ﬁgure 3), suggesting a
higher risk of women with DM to develop CAP infections.
We found a longer length of stay in patients with CAP
with DM, in line with other studies indicating signiﬁ-
cantly higher rates of hospitalization in patients with
CAP-DM.11 12 This may be attributable to effects of dia-
betes mellitus in exacerbating underlying comorbidities,
which is supported by the observation that in the young
age range (20–39 years) patients with CAP-DM showed a
higher length of stay (table 2). Indeed, Di Yacovo et al18
performed an observational analysis of a prospective
cohort of immunocompetent hospitalized adults with
CAP and found that patients with DM had distinctive
clinical features. Patients with DM had more in-hospital
acute metabolic complications18 and more severe pneu-
monia.12 23 Additionally, it has been shown that patients
with CAP with diabetes have a higher frequency of other
concomitant conditions,12 including chronic pulmonary
diseases (eg, 32.6% in CAP with DM18 and 22% in pneu-
monia with DM23).
The impact of DM in hospital mortality (table 1) was
mainly contributed by the 20–39 age group which
showed higher mortality (table 2). This is in agreement
with several other studies where patients with DM had a
higher risk of death from CAP12 24 or from pneumo-
nia.25 Kornum et al11 also reported that people with dia-
betes <40 years (15–39 years) were three times more
likely to be hospitalized with pneumonia than indivi-
duals without diabetes of similar age, with the relative
risk decreasing with ageing in individuals with DM. As
expected, type 1 diabetes was over-represented in the
youngest age group (20–39 years; 26.8%) as compared
to the 40–59 and 60–79 age groups (3.3% and 1.4%,
respectively). Nevertheless, individuals with type 1
diabetes in the youngest age group showed lower
length of hospital stay (10.2±7.1 vs 11.2±11.6) and
lower in-hospital mortality (4.2% vs 5.6%) than the
total group with DM (type 1+type 2 diabetes), indicat-
ing that inclusion of patients with type 1 diabetes did
not inﬂuence our analysis. On the other hand, we
could not ascertain whether the severity of metabolic
imbalances, namely ketoacidosis, would contribute to
the observed increased mortality in young patients with
diabetes.
Taken together, our nationwide results are in line with
other reports, suggesting that patients with DM are at
increased risk of CAP.8 9 11–14 This longitudinal study
provides indications that patients with DM acquiring
CAP are older, have a longer hospitalization time and
have higher mortality rates as compared to patients with
CAP without DM. Our study also highlights that the rela-
tive impact of diabetes was greatest in younger adults
(20–39 years) and in women. Thus, this nationwide
study identiﬁed people with DM as a priority group for
adoption of general measures to prevent CAP (eg,
smoking cessation and control of chronic illnesses), and
more speciﬁcally for ﬂu and prophylactic pneumococcal
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vaccination. These results have informative value for
strategies of patient guidance and future healthcare pol-
icies, particularly in people with diabetes under 40 years
and in women with DM.
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